Entrada Therapeutics, Inc.
6.89-0.46 (-6.26%)
Oct 29, 4:00:01 PM EDT · NasdaqGM · TRDA · USD
Key Stats
Market Cap
262.08MP/E (TTM)
-Basic EPS (TTM)
-2.03Dividend Yield
0%Recent Filings
8-K
Entrada advances DMD trials
Entrada Therapeutics dosed the first patient in its ELEVATE-44-201 Phase 1/2 trial for ENTR-601-44 in DMD exon 44-skipping patients on August 6, 2025, with Cohort 1 data expected in H1 2026. The company initiated ELEVATE-45-201 for exon 45, targeting first dosing in Q3 2025 and mid-2026 readout, while bolstering leadership with two senior VP hires. Cash stands at $354 million, funding operations into Q2 2027 despite a Q2 net loss of $43.1 million. Progress accelerates DMD pipeline momentum.
10-Q
Q2 FY2025 results
Entrada Therapeutics posted a Q2 net loss of $43.1M, up from a $55.0M profit last year, as collaboration revenue from Vertex fell to $2.0M from $94.7M y/y amid completion of VX-670 research activities. Research and development expenses climbed 18% y/y to $37.9M, driven by progress in Duchenne programs like ENTR-601-44 and ENTR-601-45, while general and administrative costs rose 18% to $10.9M. Cash and marketable securities stood at $354.0M at quarter-end, funding operations into Q2 2027. A 20% workforce reduction in April 2025 incurred $1.9M in charges to sharpen focus on clinical DMD candidates. Non-GAAP metrics not disclosed in the 10-Q. Clinical trial delays from enrollment challenges pose a key risk.
8-K
Annual meeting elects directors
Entrada Therapeutics held its 2025 Annual Meeting on June 11, electing Dipal Doshi, Kush M. Parmar, M.D., Ph.D., and Mary Thistle as Class I directors with strong support—over 27 million votes for Doshi and Thistle, though Parmar drew some withheld votes. Stockholders ratified Ernst & Young LLP as auditors for the year ending December 31, 2025, with 30.2 million in favor. Continuity intact.
8-K
Board appoints experienced CMO
Entrada Therapeutics expanded its board to seven members and appointed Maha Radhakrishnan, M.D., as a Class III director effective June 1, 2025, also joining the Audit Committee. With her background as Biogen's Chief Medical Officer and expertise in global drug development, she bolsters oversight amid advancing Duchenne muscular dystrophy programs into clinical trials. Dr. Radhakrishnan receives a $500,000-valued stock option vesting over three years. Her addition sharpens strategic focus on intracellular therapies.
8-K
EU clearance boosts DMD trials
Entrada Therapeutics secured EU regulatory clearance for its Phase 1/2 ELEVATE-44-201 study of ENTR-601-44 in Duchenne patients amenable to exon 44 skipping, building on prior U.K. and U.S. approvals. The company plans to launch this trial in Q2 2025 and ELEVATE-45-201 in Q3, while Vertex advances the partnered VX-670 for myotonic dystrophy. Cash reserves hit $382.5 million, funding operations into Q2 2027, but a 20% workforce cut sharpens focus on DMD programs amid rising R&D costs. Momentum accelerates.
CAPR
Capricor Therapeutics, Inc.
6.92+0.74
DYN
Dyne Therapeutics, Inc.
23.63-0.66
ENDV
Endonovo Therapeutics, Inc.
0.00+0.00
ENTA
Enanta Pharmaceuticals, Inc.
10.63+0.16
ENTO
Entero Therapeutics Inc.
4.46+0.51
ENVB
Enveric Biosciences, Inc.
6.70-0.42
EWTX
Edgewise Therapeutics, Inc.
16.33-0.09
SRPT
Sarepta Therapeutics, Inc.
23.45-0.77
TOVX
Theriva Biologics, Inc.
0.31-0.02
VRTX
Vertex Pharmaceuticals Incorpor
417.21-5.18